Five Prime Therapeutics, Inc. (NASDAQ:FPRX) headquartered in South San Francisco, will host a conference call for the investment community to discuss the 3Q20 financial results on 3rd November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.fiveprime.com
Earnings Expectation
Five Prime Therapeutics, Inc. is reporting third quarter earnings results on Tuesday 3rd November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.6 per share from $ 3.41 million in revenue. For the full year, analysts predict revenues of $ 18.34 million, while looking forward to loss of $ 2.24 per share.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The companys product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.
